|
Market Closed -
NYSE
16:00:02 2026-09-11 EDT
|
5-day change | 1st Jan Change | ||
| 137.16 USD | -0.23% |
|
-15.90% | -0.51% |
| 09-11 | Scholar Rock gets first FDA nod for rare muscle-wasting disease | RE |
| 09-11 | US FDA approves Scholar Rock's muscle weakness drug | RE |
| Market Cap | 261B 225B 213B 193B 362B 24,939B 364B 2,528B 972B 12,674B 980B 959B 40,083B | P/E 2026 * |
19.4x | P/E 2027 * | 16.3x |
|---|---|---|---|---|---|
| Enterprise Value | 293B 252B 239B 216B 406B 27,957B 408B 2,834B 1,090B 14,208B 1,099B 1,075B 44,933B | EV / Sales 2026 * |
5.08x | EV / Sales 2027 * | 4.71x |
| Free-Float |
91.66% | Yield 2026 * |
3.23% | Yield 2027 * | 3.38% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| NVS | Delayed | |
CBOE
| NVS | Real-time | |
|
Deutsche Boerse AG
| NOTA | Delayed | |
|
Tradegate
| NOTA | Real-time | |
|
Börse Stuttgart
| NOTA | Delayed | |
|
Boerse Muenchen
| NOTA | Real-time | |
|
Mexican S.E.
| NVS N | End-of-day quote |
Last Transcript : Novartis AG
| 1 day | -0.23% | ||
| 1 week | -15.90% | ||
| Current month | -9.80% | ||
| 1 month | -12.52% | ||
| 3 months | -7.40% | ||
| 6 months | -15.12% | ||
| Current year | -0.51% |
| 1 week | 137 |  | 140.46 |
| 1 month | 137 | | 164.48 |
| Current year | 135.55 | | 170.46 |
| 1 year | 121.57 | | 170.46 |
| 3 years | 92.19 | | 170.46 |
| 5 years | 74.09 | | 170.46 |
| 10 years | 66.93 | | 170.46 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 2018-01-31 | |
Mukul Mehta
DFI | Director of Finance/CFO | - | 2026-03-15 |
Karen Hale
CMP | Compliance Officer | 58 | 2025-04-13 |
| Director | Title | Age | Since |
|---|---|---|---|
Nancy Andrews
BRD | Director/Board Member | 67 | 2014-12-31 |
| Director/Board Member | 69 | 2015-12-31 | |
Ton Büchner
BRD | Director/Board Member | 61 | 2015-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.23% | -15.90% | - | - | 263B | |
| -0.65% | -3.79% | +47.85% | +90.24% | 1,001B | |
| -0.29% | -4.62% | +51.08% | +65.41% | 642B | |
| +0.83% | -1.19% | +21.49% | +72.54% | 451B | |
| -0.38% | -3.45% | +29.35% | +34.09% | 340B | |
| -0.09% | -14.68% | +11.22% | +27.14% | 263B | |
| -0.43% | -3.61% | -1.73% | +7.95% | 247B | |
| -1.34% | -15.03% | +35.49% | +45.45% | 207B | |
| -3.44% | -8.32% | -21.27% | -59.20% | 197B | |
| -0.75% | -4.96% | +24.70% | +89.11% | 180B | |
| Average | -0.61% | -5.53% | +22.02% | +41.41% | 391.82B | |
| Weighted average by Cap. | -0.38% | -4.65% | +31.32% | +56.55% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 57.64B 49.71B 47.04B 42.61B 79.94B 5,507B 80.41B 558B 215B 2,799B 216B 212B 8,851B | 61.32B 52.88B 50.04B 45.33B 85.04B 5,858B 85.54B 594B 228B 2,977B 230B 225B 9,415B |
| Net income | 14.19B 12.24B 11.58B 10.49B 19.68B 1,356B 19.8B 137B 52.86B 689B 53.29B 52.12B 2,179B | 15.75B 13.58B 12.85B 11.64B 21.84B 1,504B 21.97B 152B 58.66B 765B 59.13B 57.83B 2,418B |
| Net Debt | 31.58B 27.24B 25.78B 23.35B 43.8B 3,018B 44.06B 306B 118B 1,534B 119B 116B 4,850B | 27.9B 24.06B 22.77B 20.62B 38.69B 2,665B 38.92B 270B 104B 1,354B 105B 102B 4,284B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-09-11 | US$137.16 | -0.23% | 2,348,359 |
| 26-09-10 | US$137.48 | 0.00% | 2,419,869 |
| 26-09-09 | US$137.48 | -0.16% | 2,937,132 |
| 26-09-08 | US$137.70 | -13.93% | 10,273,933 |
| 26-09-04 | US$159.99 | -1.90% | 1,294,324 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NOVN Stock
- NVS Stock
Select your edition
All financial news and data tailored to specific country editions
